30
total announcements
ERIS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹15,949 Cr
P/E (TTM)
24.5
P/E (Forward)
19.9
EPS (TTM)
₹46.95
52W Low
₹1,137.90
52W High
₹1,740.00
Dividend Yield
1.25%
Beta
-0.03
Price / Book
4.0
Debt / Equity
60.5
Revenue (TTM)
₹3,212 Cr
Gross Margin
73.53%
Operating Margin
25.79%
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the securities received for dematerialisation during the quarter ended 30th September 2026.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange regarding the resignation of Mr. Krishnakumar Vaidyanathan as Executive Director and Chief Operating Officer (COO) of the company, effective September 30, 2026.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Eris Lifesciences Limited
Eris Lifesciences Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 25, 2026, and informed the Exchange regarding voting results.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026, where the company adopted audited financial statements, appointed a director, ratified cost auditors' remuneration, and re-appointed an independent director.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange regarding allotment of 155264 securities pursuant to ESOP/ESPS at its meeting held on September 22, 2026, increasing the paid-up share capital from ₹13,85,83,305/- to ₹13,87,38,569 /-.
Eris Lifesciences Limited
Eris Lifesciences Limited has appointed Mr. Akhil Awasthi as a Non-Executive Independent Director of the company, effective September 26, 2026.
Eris Lifesciences Limited
Eris Lifesciences Limited has announced the resignation of Mr. Krishnakumar Vaidyanathan as Executive Director and Chief Operating Officer (COO) effective September 30, 2026, to pursue professional opportunities outside the organization.
Eris Lifesciences Limited
Eris Lifesciences Limited has clarified a news article regarding a loan disclosure, stating that the correct value of the loan is as previously disclosed by the company.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about Loan Agreement with Axis Bank Limited for a term loan amounting to ₹45,00,00,000/- (Rupees Forty Five Crores Only). The loan will not impact the expected Net Debt figure at the end of the quarter.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about a scheduled meeting with an institutional investor, Bank of India, on September 10, 2026.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about a copy of newspaper publication regarding the Notice of Twentieth Annual General Meeting and remote E-voting of the Company.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication regarding 20th Annual General Meeting to be held on September 25, 2026, through Video Conferencing.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026, through video conferencing.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on August 31, 2026, where the Board of Directors approved the re-appointment of Mr. Sujesh Vasudevan as Independent Director of the Company for another period of 5 years, commencing from July 25, 2027, and convened the 20th Annual General Meeting of the Members of the Company on Friday, September 25, 2026.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about a scheduled meeting with institutional investors on August 27, 2026, to discuss publicly available documents.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about the schedule of an analyst/institutional investor meet/conference call on August 17, 2026, where the management will discuss publicly available documents and no unpublished price sensitive information will be disclosed.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about the schedule of an analyst/institutional investor meet/conference call on August 14, 2026, where the company's management will discuss publicly available documents and no unpublished price-sensitive information will be disclosed.
Eris Lifesciences Limited
Eris Lifesciences Limited has informed the Exchange about a Loan Agreement with Axis Bank Limited for a working capital term loan of ₹64,40,00,000 to meet other short-term liabilities.
Eris Lifesciences Limited
Eris Lifesciences Limited has made available the transcript of its Analyst and Investor call held after the announcement of financial results for the quarter ended June 30, 2026. The transcript is available on the company's website at https://eris.co.in/financials/